BEACON study will evaluate bitopertin as a potential disease-modifying treatment for patients with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP) Key assessments include changes in protoporphyrin IX levels, safety, tolerability…
Tag: Phase
Vietnam’s Hoi An city pledges to phase out dog and cat meat consumption
Hoi An, a UNESCO World Heritage Site and tourist destination, has signed a pledge with the global animal welfare organization Four Paws International. Setting a precedent Officials in the Vietnamese…
Vietnam’s Hoi An city to phase out dog and cat meat
Fast messages An estimated five million dogs are consumed each year in Vietnam, but the practice is dying out, with 88 percent advocating a ban in a recent poll. Vietnamese…
Galmed Pharmaceuticals : Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine – Form 6-K
Results from Galmed’s Phase 2b ARREST study with aramchol published in Nature Medicine – The data complements the growing body of clinical and scientific evidence demonstrating the therapeutic potential of…
New England Journal of Drugs Publishes 24-Week Outcomes from Section Three Research Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis
NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1…
Bayer Pronounces Publication of Part IV Adempas® (riociguat) Knowledge in The Lancet Respiratory Medication
WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study in which…
Bayer Declares Publication of Section IV Adempas® (riociguat) Information in The Lancet Respiratory Medication
WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study in which…
Algernon Prescription drugs to Conduct Section 1 DMT Stroke Program Examine with Hammersmith Medicines Analysis (UK)
VANCOUVER, British Columbia, March 1, 2021 (GLOBE NEWSWIRE) – Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical-stage pharmaceutical development company Announces that it…
Regeneron Publicizes Constructive Part 2 Information Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Sufferers with Gentle Bronchial asthma
TARRYTOWN, N.Y., Feb. 27, 2021 /PRNewswire/ — Single administration of novel antibody cocktail controlled patients’ allergic response to cat allergen, preventing early asthma reactions for the duration of the 3-month…